サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1636004

高コレステロール血症市場：タイプ別、診断・治療別、患者別、エンドユーザー別、地域別、2025-2033年

Hypercholesterolemia Market by Type, Diagnosis and Treatment, Patient, End User, and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 123 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
高コレステロール血症市場：タイプ別、診断・治療別、患者別、エンドユーザー別、地域別、2025-2033年
出版日: 2025年01月10日
発行: IMARC
ページ情報: 英文 123 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

高コレステロール血症の市場の世界市場規模は2024年に201億米ドルに達しました。今後、IMARC Groupは、市場は2033年までに640億米ドルに達し、2025年から2033年にかけて13.05%の成長率（CAGR）を示すと予測しています。健康志向の高まり、高齢者人口の増加、広範な研究開発（R&D）活動が市場成長を促進する主な要因です。

高コレステロール血症は、血液中の低比重リポ蛋白（LDL）が過剰になることで知られる脂質異常症です。高コレステロール血症につながる一般的な疾患には、糖尿病、多嚢胞性卵巣症候群、甲状腺機能低下、腎臓病などがあります。高コレステロール血症は長期にわたる疾患であり、胸痛、息切れ、極度の疲労感、筋力低下などが主な症状です。高コレステロール血症は生命を脅かす重篤な疾患であり、血液中の悪玉コレステロール値を低下させるとともに、肝臓での有害なコレステロールの産生を抑える薬剤が使用されます。これらの薬剤は血管壁のプラークを安定させ、特定の血栓のリスクを減らすのに役立ちます。また、心臓発作や脳卒中のリスクや血管の機能障害を軽減します。

高コレステロール血症の市場傾向：

大衆の不健康なライフスタイルの増加による高コレステロール血症の有病率の増加は、市場の成長を促進する重要な要因の一つです。これに伴い、心血管障害（CVDs）や糖尿病、腎臓合併症、甲状腺障害などの様々な慢性疾患に罹患しやすい老年人口が増加していることも、市場成長を後押ししています。さらに、健康志向の高まりや、高コレステロール血症に対する利用可能な治療法に関する意識の高まりも、他の成長促進要因として作用しています。これとともに、高コレステロール血症患者の脂質プロファイルを正常に近づけ、患者のCVD発症リスクを低減するためのさまざまな薬剤や治療法のイントロダクションが、市場の成長を大きく後押ししています。これとは別に、有効性と安全性を高めた新規薬剤クラスの開発が市場成長に弾みをつけています。さらに、高コレステロール血症を治療するために、コレステロールを減少させる他の化合物との様々な併用療法が発売され、市場成長にプラスの影響を与えています。これに加えて、内皮機能の強化、酸化ストレスによる細胞損傷の減少、アテローム性動脈硬化プラークの安定性の向上、炎症の減少など、スタチンにはいくつかの利点があるため、広く採用されていることが市場の成長を促進しています。その他の要因としては、医療インフラの全体的な改善、新薬開発のための広範な研究開発活動、家族性高コレステロール血症患者の増加などが挙げられ、市場成長の原動力になると予想されます。

本レポートで扱う主な質問

  • 世界の高コレステロール血症の市場はこれまでどのように推移し、今後どのように推移していくのか？
  • 世界の高コレステロール血症の市場における促進要因、抑制要因、機会は何か？
  • 主要な地域市場とは？
  • 最も魅力的な高コレステロール血症市場はどの国か？
  • タイプ別の市場内訳は？
  • 診断・治療別の市場内訳は？
  • 患者別の市場内訳は？
  • エンドユーザー別の市場内訳は？
  • 世界の高コレステロール血症の市場の競合構造は？
  • 高コレステロール血症の市場の世界市場における主要プレイヤー／企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の高コレステロール血症市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：タイプ別

  • タイプ1
    • 市場動向
    • 市場予測
  • タイプ2A
    • 市場動向
    • 市場予測
  • タイプ2B
    • 市場動向
    • 市場予測
  • タイプ3
    • 市場動向
    • 市場予測
  • タイプ4
    • 市場動向
    • 市場予測
  • タイプ5
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳：診断・治療別

  • 診断
    • 市場動向
    • 主要セグメント
      • コレステロール検査
      • 遺伝子検査
    • 市場予測
  • 治療
    • 市場動向
    • 主要セグメント
      • スタチン
      • ナイアシン
      • 胆汁酸樹脂
      • フィブリン酸誘導体
      • コレステロール吸収阻害剤
      • PCSK9阻害剤
      • その他
    • 市場予測

第8章 市場内訳：患者別

  • 小児
    • 市場動向
    • 市場予測
  • 成人
    • 市場動向
    • 市場予測
  • 高齢者
    • 市場動向
    • 市場予測

第9章 市場内訳：エンドユーザー別

  • 病院
    • 市場動向
    • 市場予測
  • 専門クリニック
    • 市場動向
    • 市場予測
  • 在宅医療
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第10章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ

第11章 促進要因・抑制要因・機会

  • 概要
  • 促進要因
  • 抑制要因
  • 機会

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Amgen Inc.
    • Dr. Reddy's Laboratories
    • Lupin Limited
    • Novartis AG
    • Regeneron Pharmaceuticals, Inc
図表

List of Figures

  • Figure 1: Global: Hypercholesterolemia Market: Major Drivers and Challenges
  • Figure 2: Global: Hypercholesterolemia Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Hypercholesterolemia Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Hypercholesterolemia Market: Breakup by Type (in %), 2024
  • Figure 5: Global: Hypercholesterolemia Market: Breakup by Diagnosis & Treatment (in %), 2024
  • Figure 6: Global: Hypercholesterolemia Market: Breakup by Patient (in %), 2024
  • Figure 7: Global: Hypercholesterolemia Market: Breakup by End User (in %), 2024
  • Figure 8: Global: Hypercholesterolemia Market: Breakup by Region (in %), 2024
  • Figure 9: Global: Hypercholesterolemia (Type 1) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Hypercholesterolemia (Type 1) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Hypercholesterolemia (Type 2A) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Hypercholesterolemia (Type 2A) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Hypercholesterolemia (Type 2B) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Hypercholesterolemia (Type 2B) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Hypercholesterolemia (Type 3) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Hypercholesterolemia (Type 3) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Hypercholesterolemia (Type 4) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Hypercholesterolemia (Type 4) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Hypercholesterolemia (Type 5) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Hypercholesterolemia (Type 5) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Hypercholesterolemia (Other Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Hypercholesterolemia (Other Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Hypercholesterolemia (Diagnosis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Hypercholesterolemia (Diagnosis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Hypercholesterolemia (Treatment) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Hypercholesterolemia (Treatment) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Hypercholesterolemia (Pediatric) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Hypercholesterolemia (Pediatric) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Hypercholesterolemia (Adults) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Hypercholesterolemia (Adults) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Hypercholesterolemia (Geriatric) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Hypercholesterolemia (Geriatric) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Hypercholesterolemia (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Hypercholesterolemia (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Global: Hypercholesterolemia (Specialty Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Global: Hypercholesterolemia (Specialty Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Global: Hypercholesterolemia (Home Healthcare) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Global: Hypercholesterolemia (Home Healthcare) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Global: Hypercholesterolemia (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Global: Hypercholesterolemia (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: North America: Hypercholesterolemia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: North America: Hypercholesterolemia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: United States: Hypercholesterolemia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: United States: Hypercholesterolemia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Canada: Hypercholesterolemia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Canada: Hypercholesterolemia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Asia-Pacific: Hypercholesterolemia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Asia-Pacific: Hypercholesterolemia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: China: Hypercholesterolemia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: China: Hypercholesterolemia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Japan: Hypercholesterolemia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Japan: Hypercholesterolemia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: India: Hypercholesterolemia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: India: Hypercholesterolemia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: South Korea: Hypercholesterolemia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: South Korea: Hypercholesterolemia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Australia: Hypercholesterolemia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Australia: Hypercholesterolemia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Indonesia: Hypercholesterolemia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Indonesia: Hypercholesterolemia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Others: Hypercholesterolemia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Others: Hypercholesterolemia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Europe: Hypercholesterolemia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Europe: Hypercholesterolemia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Germany: Hypercholesterolemia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Germany: Hypercholesterolemia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: France: Hypercholesterolemia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: France: Hypercholesterolemia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: United Kingdom: Hypercholesterolemia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: United Kingdom: Hypercholesterolemia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Italy: Hypercholesterolemia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Italy: Hypercholesterolemia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Spain: Hypercholesterolemia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Spain: Hypercholesterolemia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Russia: Hypercholesterolemia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Russia: Hypercholesterolemia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Others: Hypercholesterolemia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Others: Hypercholesterolemia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Latin America: Hypercholesterolemia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Latin America: Hypercholesterolemia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Brazil: Hypercholesterolemia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Brazil: Hypercholesterolemia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Mexico: Hypercholesterolemia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 84: Mexico: Hypercholesterolemia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 85: Others: Hypercholesterolemia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 86: Others: Hypercholesterolemia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 87: Middle East and Africa: Hypercholesterolemia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 88: Middle East and Africa: Hypercholesterolemia Market: Breakup by Country (in %), 2024
  • Figure 89: Middle East and Africa: Hypercholesterolemia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 90: Global: Hypercholesterolemia Industry: Drivers, Restraints, and Opportunities
  • Figure 91: Global: Hypercholesterolemia Industry: Value Chain Analysis
  • Figure 92: Global: Hypercholesterolemia Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hypercholesterolemia Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Hypercholesterolemia Market Forecast: Breakup by Type (in Million USD), 2025-2033
  • Table 3: Global: Hypercholesterolemia Market Forecast: Breakup by Diagnosis & Treatment (in Million USD), 2025-2033
  • Table 4: Global: Hypercholesterolemia Market Forecast: Breakup by Patient (in Million USD), 2025-2033
  • Table 5: Global: Hypercholesterolemia Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 6: Global: Hypercholesterolemia Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Hypercholesterolemia Market: Competitive Structure
  • Table 8: Global: Hypercholesterolemia Market: Key Players
目次
Product Code: SR112025A6678

The global hypercholesterolemia market size reached USD 20.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 64.0 Billion by 2033, exhibiting a growth rate (CAGR) of 13.05% during 2025-2033. Rising health consciousness, increasing geriatric population, and extensive research and development (R&D) activities represent some of the key factors driving the market growth.

Hypercholesterolemia is a lipid disorder known for an excess of low-density lipoprotein (LDL) in the blood. Some of the common conditions that lead to hypercholesterolemia are diabetes, polycystic ovary syndrome, underactive thyroid gland, and kidney diseases. It is a long-term condition, and chest pain, shortness of breath, extreme fatigue, and muscle weakness are some of the most common symptoms. Hypercholesterolemia is a serious life-threatening ailment wherein drugs are used to decrease the level of bad cholesterol in the blood while reducing the liver's production of harmful cholesterol. These drugs help stabilize the plaques on blood vessel walls and reduce the risk of certain blood clots. They also reduce the risk of a heart attack or stroke and dysfunction in the blood vessels.

Hypercholesterolemia Market Trends:

The growing prevalence of hypercholesterolemia due to the rising unhealthy lifestyle among the masses is one of the key factors driving the market growth. In line with this, the increasing geriatric population that is susceptible to cardiovascular disorders (CVDs) and various other chronic diseases, such as diabetes, kidney complications, and thyroid problems, is favoring the market growth. Moreover, the rising health consciousness and the increasing awareness regarding the available treatment alternatives for hypercholesterolemia are acting as other growth-inducing factors. Along with this, the introduction of various drugs and therapies to achieve near-normal lipid profiles in hypercholesterolemia patients and reduce the risk of CVDs occurrence in patients is providing a considerable boost to the market growth. Apart from this, the development of novel drug classes with enhanced efficacy and safety profile is providing an impetus to the market growth. Additionally, the launch of various combination therapies with other cholesterol-diminishing compounds to treat hypercholesterolemia is positively influencing the market growth. Besides this, the widespread adoption of statins due to their several advantages, such as enhanced endothelial function, decreased oxidative stress-induced cell damage, increased atherosclerotic plaque stability, and reduced inflammation is facilitating the market growth. Other factors, including overall improvements in the healthcare infrastructure, extensive research, and development (R&D) activities for developing novel drugs, and the increasing number of familial hypercholesterolemia patients, are anticipated to drive the market growth.

Key Market Segmentation:

Type Insights:

  • Type 1
  • Type 2A
  • Type 2B
  • Type 3
  • Type 4
  • Type 5
  • Others

Diagnosis and Treatment Insights:

  • Diagnosis
  • Cholesterol Test
  • Genetic Testing
  • Treatment
  • Statins
  • Niacin
  • Bile Acid Resins
  • Fibric Acid Derivatives
  • Cholesterol Absorption Inhibitors
  • PCSK9 Inhibitors
  • Others

Patient Insights:

  • Pediatric
  • Adults
  • Geriatric

End User Insights:

  • Hospitals
  • Specialty Clinics
  • Home Healthcare
  • Others

Regional Insights:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
  • The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for hypercholesterolemia. Some of the factors driving the North America hypercholesterolemia market included its growing prevalence of hypercholesterolemia, increasing geriatric population, and rising unhealthy lifestyle among the masses.

Competitive Landscape:

  • The report has also provided a comprehensive analysis of the competitive landscape in the global hypercholesterolemia market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Amgen Inc., Dr. Reddy's Laboratories, Lupin Limited, Novartis AG, Regeneron Pharmaceuticals, Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global hypercholesterolemia market performed so far and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global hypercholesterolemia market?
  • What are the key regional markets?
  • Which countries represent the most attractive hypercholesterolemia markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the diagnosis and treatment?
  • What is the breakup of the market based on patient?
  • What is the breakup of the market based on the end user?
  • What is the competitive structure of the global hypercholesterolemia market?
  • Who are the key players/companies in the global hypercholesterolemia market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hypercholesterolemia Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Type 1
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Type 2A
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Type 2B
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Type 3
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Type 4
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Type 5
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Diagnosis & Treatment

  • 7.1 Diagnosis
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Cholesterol Test
      • 7.1.2.2 Genetic Testing
    • 7.1.3 Market Forecast
  • 7.2 Treatment
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 Statins
      • 7.2.2.2 Niacin
      • 7.2.2.3 Bile Acid Resins
      • 7.2.2.4 Fibric Acid Derivatives
      • 7.2.2.5 Cholesterol Absorption Inhibitors
      • 7.2.2.6 PCSK9 Inhibitors
      • 7.2.2.7 Others
    • 7.2.3 Market Forecast

8 Market Breakup by Patient

  • 8.1 Pediatric
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Adults
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Geriatric
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Specialty Clinics
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Home Healthcare
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 Drivers, Restraints, and Opportunities

  • 11.1 Overview
  • 11.2 Drivers
  • 11.3 Restraints
  • 11.4 Opportunities

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Amgen Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Dr. Reddy's Laboratories
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Lupin Limited
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Novartis AG
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Regeneron Pharmaceuticals, Inc
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report